Key insights
- Rocket Lab shares are falling due to profit-taking after an initial surge driven by the upcoming SpaceX IPO. Concerns about RKLB's high valuation (90x annualized sales) and competition with SpaceX are weighing on the stock. Goldman Sachs maintains a Neutral rating, highlighting risks around Rocket Lab's expansion and Neutron program execution. The stock's high beta exacerbates downside risk amid broader market weakness.
Investing.com -- Shares of Rocket Lab USA fell -10.7% in morning trading today, pulling back sharply from levels near its all-time high as the euphoria surrounding the upcoming SpaceX IPO — which briefly sent the stock surging on the previous session — rapidly faded and gave way to aggressive profit-taking. The catalyst for the prior session’s spike was news that SpaceX had moved up its IPO timeline, with a marketing roadshow set to begin June 4, pricing on June 11, and trading commencing June 12. The stock had jumped nearly 11% at the open on May 18 before reversing and surrendering nearly all of those gains, and today’s session is extending that reversal.
The stock is priced for perfection — at a roughly $72 billion market cap on approximately $200 million in quarterly revenue, RKLB trades at around 90 times annualized sales, a multiple that only holds if the Neutron rocket program lands, scales, and successfully competes with SpaceX’s Falcon 9. Analyst price targets reinforce the valuation concern: Goldman Sachs analyst Noah Poponak maintained a Neutral rating while raising his price target to $76, noting that risks remain around Rocket Lab’s expansion plans and the successful execution of the Neutron program. The SpaceX IPO, which initially got investors excited, may now be getting them scared — as the listing date approaches, investors are beginning to weigh the competitive implications of a publicly traded SpaceX rather than simply celebrating space-sector enthusiasm.
Although RKLB is no longer a small-cap stock at a $72 billion market cap, its volatility profile still trades like one, with a beta sitting well above 2 versus the S&P 500 — meaning a 10% market drawdown can translate to a 25–40% RKLB drawdown on any Neutron headline. That dynamic is playing out today against a backdrop of broad market weakness, with the NASDAQ declining -1.1%, the S&P 500 falling -0.7%, and the Dow slipping -0.3%. A technical sell signal was issued from a pivot top point on May 14, and further downside had already been indicated until a new bottom pivot is found.
The combination of a sentiment reversal tied to the SpaceX IPO narrative, extreme valuation multiples flagged by multiple Wall Street analysts, a high-beta profile amplifying broader index weakness, and a stock that had rallied more than 60% in a matter of weeks all converged today to produce a steep pullback. Notably, Neutron — the central pillar of the bull thesis — has already slipped from 2024 to 2025 to 2026, with a propellant tank failure during testing pushing the debut to Q4 2026 at the earliest, reminding investors that execution risk remains very real at these elevated price levels.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.